Comparative Pharmacology
Head-to-head clinical analysis: NAFCILLIN SODIUM versus POLYCILLIN PRB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAFCILLIN SODIUM versus POLYCILLIN PRB.
NAFCILLIN SODIUM vs POLYCILLIN-PRB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nafcillin exerts bactericidal activity by inhibiting bacterial cell wall synthesis via binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking. It is resistant to staphylococcal beta-lactamases.
POLYCILLIN-PRB combines ampicillin and probenecid. Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Probenecid inhibits renal tubular secretion of ampicillin, increasing its plasma concentration.
1-2 g IV every 4 hours; or 1-2 g IM every 4-6 hours.
250-500 mg orally every 6 hours or 500 mg-1 g intramuscularly every 6-8 hours.
None Documented
None Documented
Approximately 0.5 hour (30 minutes) in adults with normal renal function; prolonged to 1-2 hours in neonates or severe renal impairment. Clinically relevant for dosing every 4-6 hours.
Terminal elimination half-life: 1-1.5 hours in patients with normal renal function; prolonged to 7-10 hours in anuria.
Primarily renal (30-40% unchanged) and hepatic/biliary elimination. Approximately 10-15% excreted in bile via feces.
Renal: 60-80% unchanged via glomerular filtration and tubular secretion; Biliary/fecal: 20-40% as metabolites and unchanged drug.
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic